(Reuters) - CHICAGO, June 14 - Johnson & Johnson on Thursday said its Cordis unit, which makes cardiovascular devices, has resolved its issues with the U.S. Food and Drug Administration, clearing the way for the introduction of new products.
Cordis, best known for its Cypher drug-eluting heart stent, has been operating under a warning from the FDA since April 2004. Regulators cited problems with internal procedures, including many issues with manufacturing processes.
Read more at Reuters.com Government Filings News
Cordis, best known for its Cypher drug-eluting heart stent, has been operating under a warning from the FDA since April 2004. Regulators cited problems with internal procedures, including many issues with manufacturing processes.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment